RenovaCare, Inc. is a regenerative medicine company focused on the development and commercialization of novel cell therapy technologies for the treatment of severe skin injuries and chronic wounds. The company’s core platform leverages autologous epidermal stem cells to accelerate the body’s natural healing processes, with a particular emphasis on burn trauma and non‐healing ulcers. RenovaCare’s mission is to provide patients and clinicians with advanced, minimally invasive solutions that improve outcomes and reduce scarring compared to traditional grafting techniques.
Central to RenovaCare’s product pipeline is the SkinGun® device, a handheld delivery system designed to spray a patient’s own cultured epidermal cells uniformly over the wound bed. In a single procedure, a small biopsy is processed to isolate stem cells, which are then combined with a saline solution and applied via the SkinGun. This approach promotes rapid re-epithelialization, reduces overall hospitalization time and minimizes donor site morbidity. The company has reported positive clinical data from investigator-led trials in both the United States and Mexico.
Headquartered in New York City, RenovaCare maintains research partnerships and regulatory filings across North America and Latin America. The company holds multiple patents covering its cell isolation methods, delivery device and process for wound treatment. RenovaCare continues to pursue strategic collaborations with burn centers, academic institutions and distribution partners to expand access to its technology and advance toward broader regulatory approvals.
RenovaCare is led by an experienced management team with deep expertise in biotechnology, medical device commercialization and cell therapy research. Under the leadership of CEO Thomas D. Jordan, the company remains committed to innovation in tissue regeneration and to delivering life-changing therapies for patients suffering from complex dermatological injuries.
AI Generated. May Contain Errors.
Free RCAR Stock Alerts